Compass Therapeutics (CMPX) Total Non-Current Liabilities (2019)
Compass Therapeutics (CMPX) reported Total Non-Current Liabilities of $18.6 million for Q4 2019.
Compass Therapeutics (CMPX) Total Non-Current Liabilities (2019) Analysis & Trends
Compass Therapeutics (CMPX) has 1 years of Total Non-Current Liabilities data on file, last reported at $18.6 million in Q4 2019.
- For the quarter ending Q4 2019, Total Non-Current Liabilities changed N/A year-over-year to $18.6 million; the trailing twelve-month figure through Dec 2019 stood at $18.6 million (changed N/A YoY), and the FY2019 full-year result was $18.6 million, changed N/A from the prior year.
- Total Non-Current Liabilities steadied at $18.6 million in Q4 2019.
- In the past five years, Total Non-Current Liabilities ranged from a high of $18.6 million in Q4 2019 to a low of $18.6 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 18.62 Mn |